ChenGuang Biotech Group Balance Sheet Health
Financial Health criteria checks 3/6
ChenGuang Biotech Group has a total shareholder equity of CN¥3.1B and total debt of CN¥4.0B, which brings its debt-to-equity ratio to 129.8%. Its total assets and total liabilities are CN¥7.7B and CN¥4.6B respectively. ChenGuang Biotech Group's EBIT is CN¥311.5M making its interest coverage ratio 4.9. It has cash and short-term investments of CN¥2.6B.
Key information
129.8%
Debt to equity ratio
CN¥4.04b
Debt
| Interest coverage ratio | 4.9x |
| Cash | CN¥2.55b |
| Equity | CN¥3.11b |
| Total liabilities | CN¥4.64b |
| Total assets | CN¥7.75b |
Recent financial health updates
No updates
Recent updates
A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb
Oct 08
ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively
Sep 30Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing
May 13Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)
Apr 25ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target
Apr 21Financial Position Analysis
Short Term Liabilities: 300138's short term assets (CN¥5.6B) exceed its short term liabilities (CN¥3.1B).
Long Term Liabilities: 300138's short term assets (CN¥5.6B) exceed its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 300138's net debt to equity ratio (47.7%) is considered high.
Reducing Debt: 300138's debt to equity ratio has increased from 65.7% to 129.8% over the past 5 years.
Debt Coverage: 300138's debt is not well covered by operating cash flow (0.8%).
Interest Coverage: 300138's interest payments on its debt are well covered by EBIT (4.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:11 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ChenGuang Biotech Group Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Siyuan Dong | Changjiang Securities Co. LTD. |
| Wendan Wang | China International Capital Corporation Limited |
| Guang Yao Chen | Founder Securities Co., Ltd. |